Abaloparatide for treating osteoporosis in males aged 40 to 85 years

Abaloparatide is in clinical development for the treatment of males with osteoporosis, including osteoporosis associated with hypogonadism. Osteoporosis is a condition that causes weakening of the bones, which can result in increased risk of fractures or breaks. Although osteoporosis predominately affects postmenopausal women, approximately 20-25% of men over the age of 50 years will experience osteoporotic fractures in their lifetime. In many cases the cause of osteoporosis in men is unknown, however, decreases in testosterone (a male hormone), which helps keep the bones healthy, may be a contributor. Hypogonadism is a condition which leads to a decrease of testosterone levels and is associated with an increased risk of osteoporosis.